Heidelberg Pharma AG (FRA:HPHA)

Market Cap	116.03M -43.2%
Revenue (ttm)	7.45M +78.0%
Net Income	-33.10M
EPS	-0.71
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	800
Open	2.460
Previous Close	2.500
Day's Range	2.460 - 2.460
52-Week Range	2.310 - 4.500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 9, 2026

About Heidelberg Pharma AG

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, Europe, China, the United States, and internationally. The company’s lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It also develops HDP-102, an antibody and the compound Amanitin, which has completed preclinical development for the treatment of non-Hodgkin lymphoma; HDP-103, a proprietary ATAC candidate to...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1997
• Employees: 41
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: HPHA

Financial Performance

In fiscal year 2025, Heidelberg Pharma AG's revenue was 1.46 million, a decrease of -78.72% compared to the previous year's 6.85 million. Losses were -42.28 million, 118.1% more than in 2024.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error